Raptor Pharmaceutical to raise $15 million through PIPE financing

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced it has entered into a securities purchase agreement in connection with a private placement, or PIPE financing. Upon the closing of the PIPE financing, Raptor will receive gross proceeds of approximately $15 million resulting from the sale of 4,897,614 units at a purchase price of $3.075 per unit. Each unit consists of one share of Raptor's common stock and one warrant to purchase one share of Raptor's common stock. The warrants will be exercisable for a five-year period and have an exercise price of $3.075 per share. The closing of the PIPE financing is subject to standard closing conditions.  

JMP Securities LLC served as the exclusive placement agent for the transaction.


 Raptor Pharmaceutical Corp.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study demonstrates long-term safety and clinical benefit of combination therapy for cystic fibrosis